Withholding clopidogrel for 3 to 6 versus 7 days or more before surgery in hip fracture patients

Area of Science:

• Cardiology
• Orthopedic Surgery
• Geriatric Medicine

Background:

• Clopidogrel is an antiplatelet medication commonly prescribed for patients with cardiovascular conditions.
• Managing antiplatelet therapy in patients undergoing surgery, particularly hip fracture surgery, presents a challenge due to the risk of bleeding versus thrombotic events.

Purpose of the Study:

• To compare morbidity and mortality rates in patients undergoing hip fracture surgery after withholding clopidogrel for 3-6 days versus 7 days or more.
• To evaluate the safety of shorter clopidogrel interruption periods before hip fracture surgery.

Main Methods:

• A retrospective comparison of 47 patients (24 in the 3-6 day group, 23 in the ≥7 day group) who underwent hip fracture surgery.
• Data collected included patient demographics, American Society of Anesthesiologists status, preoperative delay, length of hospital stay, perioperative hemoglobin reduction, and transfusion requirements.

Main Results:

• No significant differences in morbidity or mortality were observed between the early (3-6 days) and delayed (≥7 days) clopidogrel withholding groups.
• Mean surgical delay was 4.2 days for the early group and 8.0 days for the delayed group.
• Cardiovascular events were the primary cause of death in both groups, with similar rates between groups.

Conclusions:

• Withholding clopidogrel for less than 7 days before hip fracture surgery does not appear to increase perioperative risks.
• Shorter interruption periods of clopidogrel may be considered in hip fracture patients, balancing bleeding risk against the need for timely surgical intervention.